@prettygirlglaze's GLP-1 transformation timeline, fact-checked

What does this video actually claim?

@prettygirlglaze shows before-and-after photos claiming to document her transformation from week 12 to week 1 on GLP-1 shots. The presentation is backwards (showing the end result first), but she's documenting weight loss progress over an 11-week period using what appears to be semaglutide or a similar GLP-1 receptor agonist.

The video doesn't make specific claims about pounds lost or side effects. It's a visual transformation post that relies heavily on hashtags like #semaglutideforweightloss and #glp1forweightloss to attract viewers interested in these medications.

Does the timeline match clinical expectations?

An 11-week timeframe for noticeable weight loss on GLP-1 medications is realistic, though individual results vary widely. The STEP 1 trial showed average weight loss of 5.9% at 12 weeks with semaglutide 2.4mg, compared to 1% with placebo.

However, most patients don't reach the full 2.4mg dose until week 16 or later due to the gradual titration schedule. Patients typically start at 0.25mg weekly and increase every four weeks. This means @prettygirlglaze likely wasn't on the full therapeutic dose for most of her documented timeline.

The SCALE trial with liraglutide found 4% weight loss at 12 weeks, while the SURMOUNT-1 trial showed 7.1% loss with tirzepatide at the same timepoint. Visual changes like those shown could reasonably occur within this window.

What's missing from this transformation story?

The video provides no context about starting weight, total pounds lost, or which specific GLP-1 medication was used. This matters because semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) have different efficacy profiles and dosing schedules.

There's also no mention of diet or exercise changes. The STEP trials required lifestyle counseling alongside medication, and real-world effectiveness often depends on concurrent behavioral modifications.

The backward presentation (week 12 to week 1) is confusing and could mislead viewers about the actual progression. Most medical documentation follows chronological order for good reason.

What should you know about GLP-1 weight loss?

GLP-1 receptor agonists are FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. They work by slowing gastric emptying and affecting appetite-regulating hormones in the brain.

The medications require prescription and medical supervision. Common side effects include nausea, vomiting, and diarrhea, especially during dose escalation. The STEP trials showed 74% of participants experienced gastrointestinal side effects.

Insurance coverage varies widely, and out-of-pocket costs can exceed $1,000 monthly. The medications also require indefinite use; the STEP 1 extension study showed participants regained about two-thirds of lost weight within a year of stopping treatment.

Is this typical of what you'll see?

Individual responses to GLP-1 medications vary significantly. In the STEP 1 trial, while the average weight loss was 14.9% at 68 weeks, responses ranged from minimal to over 20% body weight reduction.

Transformation posts on social media often represent best-case scenarios rather than typical outcomes. They also can't show you the full picture including side effects, cost considerations, or long-term maintenance challenges.

The visual changes @prettygirlglaze documents are plausible for someone responding well to GLP-1 therapy over 11 weeks, but her experience shouldn't be considered guaranteed or universal.